liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases
Linköping University, Department of Biomedical and Clinical Sciences, Division of Children's and Women's Health. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Mag- tarmmedicinska kliniken. (Centre for Personalised Medicine)ORCID iD: 0000-0002-3101-9367
Karolinska Inst, Sweden.
Linköping University, Department of Computer and Information Science, The Division of Statistics and Machine Learning. Linköping University, Faculty of Arts and Sciences.ORCID iD: 0000-0002-3092-4162
Karolinska Inst, Sweden.
Show others and affiliations
2024 (English)In: Genome Medicine, E-ISSN 1756-994X, Vol. 16, no 1, article id 42Article in journal (Refereed) Published
Abstract [en]

Background Ineffective drug treatment is a major problem for many patients with immune-mediated inflammatory diseases (IMIDs). Important reasons are the lack of systematic solutions for drug prioritisation and repurposing based on characterisation of the complex and heterogeneous cellular and molecular changes in IMIDs.Methods Here, we propose a computational framework, scDrugPrio, which constructs network models of inflammatory disease based on single-cell RNA sequencing (scRNA-seq) data. scDrugPrio constructs detailed network models of inflammatory diseases that integrate information on cell type-specific expression changes, altered cellular crosstalk and pharmacological properties for the selection and ranking of thousands of drugs.Results scDrugPrio was developed using a mouse model of antigen-induced arthritis and validated by improved precision/recall for approved drugs, as well as extensive in vitro, in vivo, and in silico studies of drugs that were predicted, but not approved, for the studied diseases. Next, scDrugPrio was applied to multiple sclerosis, Crohn's disease, and psoriatic arthritis, further supporting scDrugPrio through prioritisation of relevant and approved drugs. However, in contrast to the mouse model of arthritis, great interindividual cellular and gene expression differences were found in patients with the same diagnosis. Such differences could explain why some patients did or did not respond to treatment. This explanation was supported by the application of scDrugPrio to scRNA-seq data from eleven individual Crohn's disease patients. The analysis showed great variations in drug predictions between patients, for example, assigning a high rank to anti-TNF treatment in a responder and a low rank in a nonresponder to that treatment.Conclusions We propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio's potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package (https://github.com/SDTC-CPMed/scDrugPrio).

Place, publisher, year, edition, pages
BMC , 2024. Vol. 16, no 1, article id 42
Keywords [en]
Single-cell RNA sequencing; scRNA-seq; Immune-mediated inflammatory disease; Drug prioritisation; Drug repurposing; Drug prediction
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:liu:diva-202257DOI: 10.1186/s13073-024-01314-7ISI: 001190561100002PubMedID: 38509600OAI: oai:DiVA.org:liu-202257DiVA, id: diva2:1849862
Note

Funding Agencies|European Commission grant

Available from: 2024-04-09 Created: 2024-04-09 Last updated: 2025-02-11
In thesis
1. Construction and utilization of digital twins for personalized therapeutic predictions
Open this publication in new window or tab >>Construction and utilization of digital twins for personalized therapeutic predictions
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Modern healthcare faces a significant challenge, namely that 25-70% of patients with common diseases do not benefit from standard treatments despite the availability of over 13,000 drugs registered in DrugBank. This discrepancy is likely due to these diseases' complex and heterogeneous molecular nature rather than a lack of therapeutic options. Emerging technologies have revealed the immense molecular complexity underlying common diseases. For instance, singlecell RNA sequencing (scRNA-seq) has demonstrated altered gene interactions in and across multiple cell types in numerous tissues. Furthermore, these technologies have revealed vast molecular differences between patients with the same diagnosis. There is a wide gap between this complexity and the current diagnostic and therapeutic approaches.

Aim: To bring personalized medicine one step closer to the clinic; this thesis focuses on developing digital disease models that can capture the molecular biological complexity of disease in individual patients. We aim to harness these disease models to identify optimal treatments for each individual patient.

Paper I: We started by exploring the usefulness of OMIC-based approaches for diagnostic and therapeutic predictions. Utilizing a single-cell RNA-sequenced mouse model of antigen-induced arthritis, we aimed to prioritize cell types and therapeutic targets. Initial pathway enrichment analyses did not yield relevant prioritization, prompting an investigation into network-based approaches. Multi-cellular disease models (MCDMs) for AIA and human rheumatoid arthritis were constructed, incorporating predicted cell type interactions. Centrality analysis indicated that these interactions could quantify a cell type’s relative importance in disease pathogenesis. We hypothesized that transcriptomic alterations in central cell types might reflect the MCDM, serving as potential diagnostic markers. An analysis of CD4+ T cells from patients with 13 different inflammatory diseases and healthy controls demonstrated that these profiles could discriminate between healthy and diseased states and among diseases. Furthermore, a network-based approach identified drugs targeting disease- associated changes common to multiple inflammatory diseases. Notably, one of these drugs, bezafibrate, successfully dampened inflammation in the AIA mouse model.

Paper II: Building on the insights from Paper I, we investigated multicellular network models (MNMs) with time as an additional dimension. Using seasonal allergic rhinitis (SAR) as a disease model, we analyzed time-series scRNAseq data to construct MNMs of inflammatory diseases. We identified thousands of disease-associated expression changes across multiple cell types, varying at different disease stages. Notably, upstream regulators (URs) of these changes were also stage-dependent and multidirectional. To prioritize URs for drug discovery, we focused on those causing significant expression changes in multiple cell types across all time points. This strategy was validated through similar analyses of atopic dermatitis, ulcerative colitis, and Crohn’s disease, confirming that ranked URs aligned with the efficacy of existing drugs targeting the URs in the respective diseases. Furthermore, experimental validation included targeting the top-ranked regulatory gene in SAR, which was more effective than previously discovered IL4 inhibition.

Paper III: While Paper I established the use of transcriptomic data for therapeutic predictions, it focused on overlapping disease-related changes across multiple inflammatory diseases and considered transcriptomic changes in only one cell type. Paper II indicated a potential benefit in UR prioritization in numerous cell types. However, it yielded heterogeneous results and was limited by the fact that few drugs directly target URs. Neither of these approaches was feasible for individualized drug predictions. Drawing on previous insights by us and others, we next aimed to develop digital disease models for individual patients, termed digital twins, with the capability for drug efficacy screening. We proposed scDrugPrio, a strategy utilizing single-cell scRNA-sequencing-based multicellular disease models incorporating key biological and pharmacological properties, such as varying gene expression levels, varying gene interactions within and between cell types, and drug effect. scDrugPrio was constructed based on a mouse model of arthritis and validated by improved precision/recall for known drugs and in vitro studies of predicted drugs that were FDA approved for other diseases and had not yet been tried in rheumatoid arthritis or mouse arthritis. For validation, scDrugPrio was applied to human multiple sclerosis as well as Crohn’s disease data that included tissue samples from healthy and sick tissue of all patients; scDrugPrio was able to identify relevant treatments for individual patients and could distinguish anti-TNF responders from non-responders.

Conclusion: This thesis demonstrates a framework for constructing digital disease models for personalized therapeutic predictions that might hold potential for better clinical treatment decisions. By leveraging advanced genome-wide analyses and network-based approaches, we may enhance the precision and efficacy of treatments for immune-mediated inflammatory diseases, bringing personalized medicine closer to clinical reality.

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2024. p. 119
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1925
Keywords
Digital twins, Immune-mediated inflammatory disease, Transcriptomic, Systems medicine
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:liu:diva-208620 (URN)10.3384/9789180757089 (DOI)9789180757072 (ISBN)9789180757089 (ISBN)
Public defence
2024-11-20, Belladonna, Building 511, Campus US, Linköping, 13:00 (English)
Opponent
Supervisors
Available from: 2024-10-18 Created: 2024-10-18 Last updated: 2024-10-21Bibliographically approved

Open Access in DiVA

fulltext(11160 kB)4805 downloads
File information
File name FULLTEXT01.pdfFile size 11160 kBChecksum SHA-512
139b012511e144ae5052e1e3ff11f0969103bbc31dfe48d4ed9d590316514b0c2be6e8037f96fad1e7273a69467c49d4aadc4902fb92f9b14c6028cee5808830
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Sysoev, Oleg

Search in DiVA

By author/editor
Schäfer, SamuelSysoev, OlegEklund, DesiréLilja, SandraGustafsson, MikaZhang, Huan
By organisation
Division of Children's and Women's HealthFaculty of Medicine and Health SciencesMag- tarmmedicinska klinikenThe Division of Statistics and Machine LearningFaculty of Arts and SciencesDivision of NeurobiologyBioinformaticsFaculty of Science & Engineering
In the same journal
Genome Medicine
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 4806 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 292 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf